BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares shot up 3.4% on Friday . The company traded as high as $3.09 and last traded at $3.08, with a volume of 402,724 shares trading hands. The stock had previously closed at $2.98.

A number of research firms have recently weighed in on BCRX. FBR & Co reissued a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, July 6th. Jefferies Group raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, June 1st. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, May 9th. Finally, Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 11th. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and an average target price of $9.70.

The stock has a 50-day moving average price of $3.04 and a 200-day moving average price of $3.63. The stock’s market capitalization is $226.97 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.08. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. The business had revenue of $4.82 million for the quarter, compared to analysts’ expectations of $5.42 million. The business’s revenue was down 29.4% on a year-over-year basis. On average, equities analysts forecast that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current year.

Other hedge funds recently bought and sold shares of the company. Globeflex Capital L P bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth $1,241,000. Jennison Associates LLC raised its position in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the period. Finally, Morgan Stanley raised its position in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares during the period.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.